Navigation Links
Franklin Square to study airway bypass procedure for severe emphysema
Date:10/27/2008

October 27, 2008 (Baltimore, MD)Franklin Square Hospital Center announces the start of the EASE (Exhale Airway Stents for Emphysema) Trial to explore an investigational treatment for advanced widespread emphysema/COPD. The trial focuses on airway bypass, a bronchoscopic procedure designed to reduce lung hyperinflation and shortness of breath (the clinical hallmarks of emphysema/COPD) by making new pathways for trapped air to exit the lungs.

During the airway bypass procedure, new openings are created in the airway wall connecting the damaged lung tissue to the natural airway. These pathways are supported and kept open by Exhale Drug-Eluting Stents manufactured by Broncus Technologies, Inc. Patients could see an immediate improvement in dyspnea (shortness of breath).

"We are excited to be part of this study because currently there are limited treatment options for emphysema. Patients are often in poor physical condition, struggling with each breath," states William Krimsky, MD, director of Interventional Pulmonology at Franklin Square and principal investigator of the study. "By creating new pathways for airflow with the airway bypass procedure, we hope to reduce hyperinflation and improve lung function. If patients can breathe easier it is likely to improve their quality of life."

Emphysema, a component of COPD, is a chronic, progressive, and irreversible lung disease characterized by the destruction of lung tissue. The loss of the lungs' natural elasticity and the collapse of airways in the lung combine to make exhalation ineffective, leaving emphysema sufferers with hyperinflation because they are unable to get air out of their lungs. Breathing becomes inefficient and patients have to work very hard just to breathe making normal activities, like walking, eating or even bathing, difficult. There are few treatment options for most patients with emphysema and there is no cure.

"The airway bypass procedure could be an excellent option for those who are not suitable candidates for lung transplant surgery or who would possibly spend years on a lung transplant list," states Krimsky. "Given that emphysema, which permanently destroys lung function, is such a devastating disease -- any potential new treatment option could offer substantial relief to the millions who suffer."

Physicians commonly use bronchoscopes to examine the airways within the lungs. During the airway bypass procedure physicians will first use a Doppler probe inserted through the bronchoscope to identify a site in the airway that is away from blood vessels. A special needle is then used to make a small opening and an Exhale Drug-Eluting Stent is placed in the passageway to keep it open. The procedure involves placing up to six drug-eluting stents. The total time of the procedure is approximately two hours.

Although this procedure is still under clinical investigation, feasibility data suggest it may hold promise for patients with emphysema. Results from the open-label Exhale Drug-Eluting Stent feasibility study were published in the October 2007 issue of the Journal of Thoracic and Cardiovascular Surgery. Positive results included a statistically significant reduction in the amount of air trapped in the lungs and an improvement in breathing for patients at six months after the airway bypass procedure.


'/>"/>

Contact: Meghan Oreste
moreste@comcast.net
617-823-1441
Broncus Technologies
Source:Eurekalert  

Related biology news :

1. 55th anniversary of Nobel honoring double helix continues to overlook the late Rosalind Franklin
2. UMass Medical School researcher Victor Ambros receives Gairdner Award, Franklin Medal
3. Study may explain exercise-induced fatigue in muscular dystrophies
4. First comprehensive genomic study of common cold reveals new treatment targets
5. New study shows drinking your vegetables may be a solution to bridging the vegetable gap
6. New Study Reveals the Emotional Impact and Effectiveness of Negative Campaigning
7. Study: Elderly Women can increase strength but still risk falls
8. Greenhouse gas auction revenues can help cut Md. electric use significantly, says study
9. The Marine Mammal Center begins new leptospirosis study in California
10. UCSB study finds physical strength, fighting ability revealed in human faces
11. U of MN study shows link between gene variations and cancer survival
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Franklin Square to study airway bypass procedure for severe emphysema
(Date:6/16/2016)... , June 16, 2016 ... size is expected to reach USD 1.83 billion ... Grand View Research, Inc. Technological proliferation and increasing ... applications are expected to drive the market growth. ... , The development of advanced multimodal ...
(Date:6/3/2016)... 2016 Das DOTM ... Nepal hat ein 44 Millionen ... Kennzeichen, einschließlich Personalisierung, Registrierung und IT-Infrastruktur, an ... und Implementierung von Identitätsmanagementlösungen. Zahlreiche renommierte internationale ... teilgenommen, aber Decatur wurde als konformste und ...
(Date:5/24/2016)... 24, 2016 Ampronix facilitates superior patient care by providing unparalleled technology to ... display is the latest premium product recently added to the range of products distributed ... ... ... Imaging- LCD Medical Display- Ampronix News ...
Breaking Biology News(10 mins):
(Date:6/27/2016)... , ... June 27, 2016 , ... Parallel 6 ... trials, announced today the Clinical Reach Virtual Patient Encounter CONSULT module which ... with the physician and clinical trial team. , Using the CONSULT module, patients and ...
(Date:6/27/2016)... --  Ginkgo Bioworks , a leading organism design ... awarded as one of the World Economic Forum,s ... innovative companies. Ginkgo Bioworks is engineering biology to ... in the nutrition, health and consumer goods sectors. ... including Fortune 500 companies to design microbes for ...
(Date:6/24/2016)... NC (PRWEB) , ... June 24, 2016 , ... Researchers ... the most commonly-identified miRNAs in people with peritoneal or pleural mesothelioma. Their findings are ... to read it now. , Diagnostic biomarkers are signposts in the blood, lung ...
(Date:6/23/2016)... 23, 2016 /PRNewswire/ - FACIT has announced the ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" or ... of a portfolio of first-in-class WDR5 inhibitors for ... as WDR5 represent an exciting class of therapies, ... medicine for cancer patients. Substantial advances have been ...
Breaking Biology Technology: